Lymphatic Drainage of the Breast, a Retrospective Assessment of Data

• Sponsor: Dr. Elisabeth Würinger (Other)
• Overall Status: Completed
• CT.gov ID: NCT05064215
• Collaborator: (none)
• Enrollment: 14
• Location: 1
• Actual Duration (Months): 2.5
• Patients Per Site Per Month: 5.5

Study Details

Study Description

Brief Summary

retrospective evaluation of patients, in whom blue colour was injected into different sites of the breast before breast reduction, to investigate direction and localisation of lymphatic flow. Investigations were performed at the Wilhelminenspital, Vienna, in the years 1998 to 2009.

Condition or Disease	Intervention/Treatment	Phase
Lymph Drainage of Breast	Procedure: anatomical examination

Study Design

• Study Type: Observational
• Actual Enrollment: 14 participants
• Observational Model: Cohort
• Time Perspective: Retrospective
• Official Title: Lymphatic Drainage of the Breast, a Retrospective Assessment of Data
• Actual Study Start Date: May 25, 2021
• Actual Primary Completion Date: Jul 10, 2021
• Actual Study Completion Date: Aug 10, 2021

Arms and Interventions

Arm	Intervention/Treatment
injection behind NAC in 7 breasts dye was injected behind the nipple areola complex before breast reduction	Procedure: anatomical examination; After injection of dye, its distribution along lymphatic clearance paths was investigated
Injection into lateral upper quadrant in 5 breasts dye was injected into upper lateral glandular tissue before breast reduction	Procedure: anatomical examination; After injection of dye, its distribution along lymphatic clearance paths was investigated
injection into medial upper quadrant in 2 breasts dye was injected into upper medial glandular tissue before breast reduction	Procedure: anatomical examination; After injection of dye, its distribution along lymphatic clearance paths was investigated

Outcome Measures

Primary Outcome Measures

1. Lymphatic flow is guided by the ligamentous suspension [The ligamentous suspension (horizontal septum, vertical ligaments merging into superficial fascia) is exposed in the course of breast reduction in the technique, that I described usually within about 40 minutes]

   colour gathered along horizontal septum

Eligibility Criteria

Criteria

• Ages Eligible for Study: 20 Years and Older
• Sexes Eligible for Study: Female

Inclusion Criteria: Patients, who understood and supported the aim of the study and signed the written consent -

Exclusion Criteria: language barriers, patients, who did not understand and support the aim of the study

-

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Elisabeth Wuringer	Wien	Österreich	Austria	1130

Sponsors and Collaborators

• Dr. Elisabeth Würinger

Investigators

• Principal Investigator: Elisabeth Würinger, Dr. Elisabeth Würinger

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Dr. Elisabeth Würinger, Dr. Elisabeth Würinger, Wilhelminenspital Vienna
• ClinicalTrials.gov Identifier: NCT05064215
• Other Study ID Numbers: EK 21-102-VK
• First Posted: Oct 1, 2021
• Last Update Posted: Oct 1, 2021
• Last Verified: Sep 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Study Results

No Results Posted as of Oct 1, 2021